Lupin Limited on Thursday (20) announced that its Europe-based ophthalmology-focused subsidiary VISUfarma BV has entered into a licensing agreement with US-based Visus Therapeutics Inc, to market its eye drops Yuvezzi in Europe.
VISUfarma will enjoy exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution and sale of Yuvezzi, an eye drop to treat presbyopia, in the European Union, the United Kingdom, Switzerland, Norway and Iceland.
Under the agreement, VISUfarma will make a strategic investment in Visus, a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited.
Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales.
Lupin Chief Executive Officer Vinita Gupta said: “We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy.
"Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets.
"The addition of Yuvezzi underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care.”
Tenpoint Chief Executive Officer Henric Bjarke said, "This exciting partnership marks an important step for Tenpoint as we continue our work to make Yuvezzi available for the millions of patients with presbyopia.”
"Lupin’s strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma’s longstanding presence in eyecare makes them an excellent partner."
